Literature DB >> 26743766

Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants.

P F Halloran1,2, M Merino Lopez1, A Barreto Pereira1,3.   

Abstract

The key lesions in antibody-mediated kidney transplant rejection (ABMR) are microcirculation inflammation (peritubular capillaritis and/or glomerulitis lesions, abbreviated "pg") and glomerular double contours (cg lesions). We used these features to explore subphenotypes in 164 indication biopsies with ABMR-related diagnoses: 137 ABMR (109 pure and 28 mixed with T cell-mediated rejection [TCMR]) and 27 transplant glomerulopathy (TG), identified from prospective multicenter studies. The lesions indicated three ABMR subphenotypes: pgABMR, cgABMR, and pgcgABMR. Principal component analysis confirmed these subphenotypes and showed that TG can be reclassified as pgcgABMR (n = 17) or cgABMR (n = 10). ABMR-related biopsies included 45 pgABMR, 90 pgcgABMR, and 25 cgABMR, with four unclassifiable. Dominating all time intervals was the subphenotype pgcgABMR. The pgABMR subphenotype presented earliest (median <2 years), frequently mixed with TCMR, and was most associated with nonadherence. The cgABMR subphenotype presented late (median 9 years). Subphenotypes differed in their molecular changes, with pgABMR having the most histologic-molecular discrepancies (i.e. potential errors). Donor-specific antibody (DSA) was not identified in 29% of pgcgABMR and 46% of cgABMR, but failure rates and molecular findings were similar to cases where DSA was known to be positive. Thus, ABMR presents distinct subphenotypes, early pg-dominant, late cg-dominant, and combined pgcg phenotype, differing in time, molecular features, accompanying TCMR, HLA antibody, and probability of nonadherence. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  antibody-mediated (ABMR); basic (laboratory) research; gene array; kidney transplantation; microarray; nephrology; rejection; science

Mesh:

Substances:

Year:  2016        PMID: 26743766     DOI: 10.1111/ajt.13551

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  24 in total

1.  Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.

Authors:  Jeff Reeve; Georg A Böhmig; Farsad Eskandary; Gunilla Einecke; Carmen Lefaucheur; Alexandre Loupy; Philip F Halloran
Journal:  JCI Insight       Date:  2017-06-15

Review 2.  Transplant genetics and genomics.

Authors:  Joshua Y C Yang; Minnie M Sarwal
Journal:  Nat Rev Genet       Date:  2017-03-13       Impact factor: 53.242

3.  Longitudinal immunological characterization of the first presensitized recipient of a face transplant.

Authors:  Thet Su Win; Naoka Murakami; Thiago J Borges; Anil Chandraker; George Murphy; Christine Lian; Victor Barrera; Shannan Ho Sui; David Schoenfeld; Jessica Teague; Ericka Bueno; Stefan G Tullius; Bohdan Pomahac; Rachael A Clark; Leonardo V Riella
Journal:  JCI Insight       Date:  2017-07-06

4.  RNA expression profiling of renal allografts in a nonhuman primate identifies variation in NK and endothelial gene expression.

Authors:  R N Smith; B A Adam; I A Rosales; M Matsunami; T Oura; A B Cosimi; T Kawai; M Mengel; R B Colvin
Journal:  Am J Transplant       Date:  2018-02-02       Impact factor: 8.086

5.  Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

Authors:  Olivier Aubert; Alexandre Loupy; Luis Hidalgo; Jean-Paul Duong van Huyen; Sarah Higgins; Denis Viglietti; Xavier Jouven; Denis Glotz; Christophe Legendre; Carmen Lefaucheur; Philip F Halloran
Journal:  J Am Soc Nephrol       Date:  2017-03-02       Impact factor: 10.121

6.  The Biology and Molecular Basis of Organ Transplant Rejection.

Authors:  Philip F Halloran; Gunilla Einecke; Majid L N Sikosana; Katelynn Madill-Thomsen
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Lack of Histological and Molecular Signature Response to Tocilizumab in Kidney Transplants with Chronic Active Antibody Mediated Rejection: A Case Series.

Authors:  Dhiren Kumar; Idris Yakubu; Frough Safavi; Marlon Levy; Irfan Moinuddin; Pamela Kimball; Layla Kamal; Anne King; Davis Massey; Philip Halloran; Gaurav Gupta
Journal:  Kidney360       Date:  2020-04-27

Review 8.  Molecular assessment of disease states in kidney transplant biopsy samples.

Authors:  Philip F Halloran; Konrad S Famulski; Jeff Reeve
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

9.  The immunohistochemical expression of von Willebrand factor, T-cadherin, and Caveolin-1 is increased in kidney allograft biopsies with antibody-mediated injury.

Authors:  André Costa Teixeira; Fábio Távora; Melissa Lou Fagundes de Deus E Silva; Renan Martins Gomes Prado; Ronaldo de Matos Esmeraldo; Tainá Veras de Sandes-Freitas
Journal:  Clin Exp Nephrol       Date:  2020-11-26       Impact factor: 2.801

10.  Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine.

Authors:  Mirela Maier; Tomoko Takano; Ruth Sapir-Pichhadze
Journal:  Can J Kidney Health Dis       Date:  2017-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.